Krzysztof Grudziński
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Krzysztof Grudziński has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Damian Palus
Department of Hypertension and Diabetology, Faculty of Medicine, Medical University of Gdańsk, 17 Mariana Smoluchowskiego Street, 80-214 Gdańsk, Poland
2 shared publications - Krzysztof Kuziemski
Department of Pulmonology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 78 Jagiellońska Street, 10-357 Olsztyn, Poland
2 shared publications - Tomasz Stefaniak
University Clinical Centre, Medical University of Gdańsk, 7 Dębinki Street, 80-952 Gdańsk, Poland
2 shared publications - Alan Majeranowski
Department of Cell Biology and Immunology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1 Street, 80-211 Gdańsk, Poland
1 shared publication - Dariusz Kozłowski
Department of Cardiology and Electrotherapy, Faculty of Medicine, Medical University of Gdansk, 80-210 Gdansk, Poland
1 shared publication - Martyna Ewa Gołębiewska
Faculty of Medicine, Department of Psychiatry, Medical University of Gdansk, Gdansk, Poland
1 shared publication
Latest Publications
- Open Access
In-Hospital Complications Associated with Mortality in Patients Hospitalized for COVID-19: A Prospective Single-Center Cohort Study
Background and Objectives: We assessed associations of variables recorded within 24 h of admission and in-hospital complications with mortality in adults hospitalized for COVID-19. Materials and Methods: This prospective single-center cohort included 249 adults hospitalized in 2021. Four mortality classifiers underwent repeated cross-validation and 0.632+ bootstrap validation, a resampling method that combines apparent and out-of-bag performance while adjusting for overfitting. Separate logistic regressions evaluated mortality and acute kidney injury (AKI), with AKI specifications including or excluding baseline renal laboratory predictors. Results: In-hospital mortality was 22.5%. The 0.632+ bootstrap estimates of the area under the receiver operating characteristic curve were 0.862 for random forest, 0.769 for ridge logistic regression, 0.757 for linear discriminant analysis, and 0.552 for quadratic discriminant analysis. Higher lymphocyte count was associated with lower odds of death (odds ratio 0.237; 95% confidence interval 0.089–0.632). AKI, shock, and renal replacement therapy were associated with high conditional mortality. Conclusions: Admission-assessment variables provided exploratory prognostic information on in-hospital mortality in adults hospitalized for COVID-19. Sparse events, incomplete covariate information, and the single-center setting limit inference. Independent validation, calibration, and assessment of clinical benefit are required before implementation.
Open AccessIn-Hospital Complications Associated with Mortality in Patients Hospitalized for COVID-19: A Prospective Single-Center Cohort Study
Background and Objectives: We assessed associations of variables recorded within 24 h of admission and in-hospital complications with mortality in adults hospitalized for COVID-19. Materials and Methods: This prospective single-center cohort included 249 adults hospitalized in 2021. Four mortality classifiers underwent repeated cross-validation and 0.632+ bootstrap validation, a resampling method that combines apparent and out-of-bag performance while adjusting for overfitting. Separate logistic regressions evaluated mortality and acute kidney injury (AKI), with AKI specifications including or excluding baseline renal laboratory predictors. Results: In-hospital mortality was 22.5%. The 0.632+ bootstrap estimates of the area under the receiver operating characteristic curve were 0.862 for random forest, 0.769 for ridge logistic regression, 0.757 for linear discriminant analysis, and 0.552 for quadratic discriminant analysis. Higher lymphocyte count was associated with lower odds of death (odds ratio 0.237; 95% confidence interval 0.089–0.632). AKI, shock, and renal replacement therapy were associated with high conditional mortality. Conclusions: Admission-assessment variables provided exploratory prognostic information on in-hospital mortality in adults hospitalized for COVID-19. Sparse events, incomplete covariate information, and the single-center setting limit inference. Independent validation, calibration, and assessment of clinical benefit are required before implementation.
- Open Access
- 25 February 2025
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 32 (2) , 120-129
Association of pre-existing comorbidities and complications with inpatient COVID-19 mortality — a single-center retrospective study
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors
- 25 February 2025
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 32 (2) , 120-129
Open AccessAssociation of pre-existing comorbidities and complications with inpatient COVID-19 mortality — a single-center retrospective study
Background: This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates. Methods: A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing. Results: The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97–4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12–5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63–3.61), and heart failure (OR 2.89; 95% CI, 1.91–4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81–197.87), myocardial infarction (OR 25.43; 95% CI, 3.16–204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49–56.51), sepsis (OR 7.22, 95% CI, 3.77–13.84), stroke, further increased mortality risk. Conclusions: COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature. Keywords: COVID-19 complications SARS-CoV-2 comorbidity in-hospital mortality risk factors